Silex Systems

What Silex Systems does

Silex Systems Limited (ASX: SLX; OTCQX: SILXY) is an Australian high-technology company founded in 1988 and headquartered at Lucas Heights, Sydney, that commercialises the proprietary SILEX (Separation of Isotopes by Laser Excitation) laser-based isotope separation technology. SILEX is a third-generation enrichment process that uses highly selective laser excitation of isotopic molecules (initially UF6) and is the only laser-based enrichment technology globally to have achieved Technology Readiness Level 6, which it reached at GLE's Wilmington, North Carolina test loop in October 2025. The platform is applied across three end-markets: uranium enrichment for nuclear power (the commercial lead application), silicon-28 enrichment for silicon quantum computing (the Q-Si Production Project, launched August 2023 with Silicon Quantum Computing and UNSW Sydney), and medical isotope enrichment for cancer therapies (the MIST Project, early stage).

Silex operates as a B2B technology licensing and royalty company rather than a direct product vendor. Its principal commercial vehicle is Global Laser Enrichment (GLE), a 51/49 joint venture with Cameco Corporation (the world's second-largest uranium miner) established in 2006, which holds the exclusive worldwide licence to SILEX for uranium enrichment. Silex's revenue mechanics consist of a perpetual minimum 7% royalty on GLE's SWU (Separative Work Unit) revenues from use of SILEX (independent of its 51% equity stake), plus US$20 million in contractually defined milestone payments tied to TRL-6 demonstration (achieved), PLEF Engineering Procurement and Construction commencement, and PLEF commercial operations. Current annual revenue is approximately A$15 million with forecast 91% annual growth, and the company is presently operating at a loss while it funds technology maturation. The flagship forward-looking commercial asset is the planned US$1.76 billion Paducah Laser Enrichment Facility in Kentucky, designed to produce up to 5 million pounds of uranium oxide annually for up to 30 years, leveraging a 2016 GLE agreement with the US Department of Energy for over 200,000 metric tonnes of depleted UF6 feedstock.

The GTM motion is enterprise technology licensing and government engagement: Silex monetises its technology exclusively through GLE (uranium) and the SQC/UNSW consortium (quantum silicon), with regulatory approval processes (US NRC licensing, US DOE task orders, Australian government classification) functioning as both gating milestones and moat-deepening assets. The company is dual-listed on the ASX and US OTCQX International, with coverage from Canaccord Genuity, Euroz Hartleys, and Shaw and Partners. Dr Michael Goldsworthy, co-inventor of SILEX, remains Managing Director and CEO.

Name

Silex Systems

Legal name

Silex Systems Limited

Website

https://silex.com.au

Company type

Public

Founded year

1988

Operating status

Operating

Headcount range

11–50 employees

Short description

Silex Systems (ASX: SLX) is an Australian technology company commercialising the proprietary SILEX laser-based isotope separation technology, serving the uranium enrichment, quantum silicon, and medical isotope markets through licensing arrangements. Its primary vehicle is the 51/49 GLE joint venture with Cameco, targeting the planned $1.76B Paducah Laser Enrichment Facility.

Ownership category

akta.pro rank

Product category

Laser Isotope Separation Technology

NAICS

Industrial Gas Manufacturing (32512), Chemical Manufacturing (325)

SIC

Metal Mining (1000)

akta.pro industry

PRIMARYEUAKACAD

Uranium Enrichment Services (Centrifuge/Laser, SWU Supply)

Energy, Utilities & Environment/Nuclear Energy/Nuclear Fuel Cycle (Mining, Conversion, Enrichment & Fuel Fabrication)

SECONDARYEUAKACAH

HALEU Production & Supply Chain (Feedstock, Enrichment, Downblending)

Energy, Utilities & Environment/Nuclear Energy/Nuclear Fuel Cycle (Mining, Conversion, Enrichment & Fuel Fabrication)

SECONDARYEUAKAIAA

Medical Radioisotope Production (Reactor/Cyclotron, Mo-99/Tc-99m, I-131, Lu-177, etc.)

Energy, Utilities & Environment/Nuclear Energy/Nuclear Materials, Radiation Services & Isotopes (Medical/Industrial)

SECONDARYHLAIAGAD

Radioisotope Production (Reactor/Cyclotron/Gamma)

Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine

SECONDARYEUAKAIAD

Radiation Therapy Isotopes & Sources (Brachytherapy seeds, sealed sources for oncology)

Energy, Utilities & Environment/Nuclear Energy/Nuclear Materials, Radiation Services & Isotopes (Medical/Industrial)

Keywords

• Laser isotope separation
• Uranium enrichment technology
• Quantum silicon production
• Medical isotope enrichment
• Nuclear fuel technology

Headquarters

HQ city

Sydney

HQ country

Australia

HQ region

Oceania

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Technology Licensing Royalties: Perpetual royalty of minimum 7% payable to Silex on GLE's enrichment (SWU - Separative Work Unit) revenues from use of the SILEX technology. Royalty is independent of Silex's 51% equity interest in GLE.
2. Milestone Payments: US$20 million in milestone payments triggered by commercial development milestones: US$5 million for commercial pilot demonstration (TRL-6 achieved), US$5 million for commencement of PLEF Engineering Procurement and Construction (EPC), and US$10 million for PLEF commercial operations.
3. Revenue from Operations: Silex generates approximately A$15 million in revenue with forecast 91% annual growth but currently operates at a loss.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Silex Systems commercialises its proprietary SILEX (Separation of Isotopes by Laser Excitation) laser-based isotope separation technology across three applications: uranium enrichment for nuclear power (via the Global Laser Enrichment joint venture with Cameco, 51% Silex / 49% Cameco), production of highly enriched silicon-28 (Quantum Silicon, or Q-Si) for silicon quantum computing processors, and Medical Isotope Separation Technology (MIST) for new cancer therapies. The company licenses its technology and generates revenue from royalties, milestone payments, and equity participation in joint ventures.

Product overview

Silex Systems is an Australian technology company commercializing its proprietary SILEX laser-based isotope separation technology across three key applications: uranium enrichment for nuclear power (via majority-owned Global Laser Enrichment joint venture with Cameco), quantum silicon production for quantum computing (Q-Si Project with Silicon Quantum Computing and UNSW), and medical isotope enrichment for cancer therapies (MIST Project). The core SILEX technology is a third-generation laser-based process offering higher efficiency and lower capital costs compared to traditional gas-centrifuge methods, with the Paducah Laser Enrichment Facility planned as the flagship commercial deployment.

Differentiator

Problem solved

Functional benefit

Products and services

• SILEX Uranium Enrichment Technology Laser-based uranium enrichment application licensed exclusively to Global Laser Enrichment (GLE), enabling production of natural grade UF6, low enriched uranium (LEU), LEU+, and high assay low enriched uranium (HALEU) for conventional nuclear reactors and advanced reactors including small modular reactors (SMRs). Targeted at nuclear utilities, fuel buyers, and government agencies.
• Quantum Silicon (Q-Si) Production Project Project to establish first production module for highly enriched silicon-28 (Zero-Spin Silicon) for silicon quantum computing processors, producing up to 20kg annually of Q-Si. The Q-Si product eliminates Si-29 isotope which prevents effective quantum computing performance. Silex retains 100% ownership of Q-Si production technology and IP.
• Medical Isotope Separation Technology (MIST) Early-stage research activities for medical isotope enrichment using the SILEX laser-based enrichment approach, targeting new cancer therapies. Applies the SILEX platform to produce enriched medical isotopes such as Ytterbium and Molybdenum for diagnostic and therapeutic applications.

Quantifiable outcome

• Up to 5 million pounds uranium oxide equivalent annually for up to 30 years - equivalent to a top 10 uranium mine
• +2 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• US Nuclear Regulatory Commission (NRC)coreStrategic or Co-development Partner · 1 January 2026NRC received GLE's full licence application in July 2025 for the planned Paducah Laser Enrichment Facility, kickstarting an 18-month formal review process. GLE is the first company in line with the NRC to seek a licence for a new uranium enrichment facility in the US.
• Silicon Quantum Computing Pty Ltd (SQC)coreStrategic or Co-development Partner · 1 August 2023SQC is the initial offtake partner for Silex's Q-Si Production Project, contributing $4.35m in cash funding. SQC is a commercial spin-out from UNSW and world leader in silicon-based quantum computing technology. The project aims to establish first production module for highly enriched silicon-28.
• UNSW Sydney (University of New South Wales)coreStrategic or Co-development Partner · 1 August 2023UNSW is a research partner in the Q-Si Production Project, contributing expertise in silicon-based quantum computing. UNSW and SQC are world leaders in developing silicon quantum computing technology. The project is supported by $5.1m in funding from Federal Government's Defence Trailblazer for Concept to Sovereign Capability program.
• US Department of Energy (DOE)coreStrategic or Co-development Partner · 1 January 20162016 landmark agreement between GLE and US DOE for purchase of over 200,000 metric tonnes of depleted uranium hexafluoride (tails material from DOE's Paducah gaseous diffusion facility). This feedstock will support PLEF operations for up to 30 years. DOE has also awarded $2.7 billion in uranium enrichment task orders including $28 million to GLE.
• Cameco CorporationcoreStrategic or Co-development Partner · 1 January 2006Cameco holds 49% stake in Global Laser Enrichment (GLE), the exclusive licensee of SILEX technology for uranium enrichment. Silex holds 51% and is the majority owner. GLE is the first company in the world to have demonstrated large-scale, third-generation laser-based enrichment technology at TRL-6. Cameco is the world's second-largest uranium miner and provides operational expertise and market access.
• Computershare Registry ServicesminorOthersEngaged to undertake all registry services for Silex including shareholder record maintenance, document management, and investor enquiries.
• Bank of New York MellonminorOthersActs as Principal American Liaison (PAL) for Silex's Level 1 ADR program on OTCQX. ADRs trade under symbol SILXY with ratio of 1 ADR : 5 ordinary shares.

Scale indicators12 records

Recent moves7 records

Expansion highlights6 records

Emerging players

• Energy Fuels: Energy Fuels is a US-focused uranium and rare earth producer that has been expanding into uranium conversion and downstream nuclear fuel services. It is an emerging nuclear fuel supply chain player sharing Silex's Western supply security thesis.
• BWX Technologies (BWXT): BWXT is a US-based supplier of nuclear components and fuel including HALEU production via advanced manufacturing. As an emerging player in the HALEU/advanced-reactor fuel space, BWXT overlaps with Silex's target market of next-generation reactor fuel suppliers.
• Silicon Quantum Computing Pty Ltd (SQC): SQC is Silex's initial offtake partner for the Q-Si Production Project. As a UNSW spin-out commercialising silicon quantum computing, SQC is an emerging player positioned as both a customer and downstream ecosystem participant to Silex's Q-Si enrichment.

Broad incumbents

• Orano: Orano (formerly Areva) is a French multinational covering the full nuclear fuel cycle - mining, conversion, enrichment, and fuel fabrication. As a broad incumbent, it competes with Silex in uranium enrichment and serves overlapping utility/nuclear fuel customers globally.
• Rosatom / TENEX: Rosatom (and its trading arm TENEX) is the Russian state-owned nuclear conglomerate dominating global uranium enrichment via centrifuge technology. While Western sanctions limit its US market access, it remains the largest low-cost enrichment supplier globally and a benchmark for SILEX economics.
• Honeywell (Urenco stake & nuclear): Honeywell holds a stake in Urenco and operates related nuclear-grade materials businesses. It is a broad incumbent competing with Silex in adjacent areas of the nuclear supply chain and industrial isotope-related technologies.
• Cameco Corporation: Cameco is the world's second-largest uranium miner and the 49% JV partner in Global Laser Enrichment. Beyond its GLE stake, Cameco operates across uranium mining, conversion (as part-owner of Springfields), and fuel services, competing broadly across the nuclear fuel supply chain.

Direct peers

• Urenco: Urenco is one of the world's leading uranium enrichment companies operating gas centrifuge technology in the US, UK, Germany, and Netherlands. It is the closest direct peer to Silex/GLE as a commercial-scale enrichment competitor targeting utilities and government agencies for LEU/HALEU supply.
• Centrus Energy: Centrus is a US-based uranium enrichment company producing LEU and building out HALEU production capacity using centrifuge technology. It is a direct peer competing for the same Western utility customers and HALEU/SMR fuel opportunities that Silex/GLE are targeting.

Others

• Curium (radiopharmaceuticals): Curium is one of the largest nuclear medicine companies producing Mo-99 and other medical isotopes used in cancer diagnostics and therapy. It represents the downstream radiopharmaceutical market that Silex's MIST (Medical Isotope Separation Technology) is intended to serve.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Silex Systems